Tucidinostat: all 160 studies that test it
Page 1 of 2. Open to participants first (73), then studies with results posted, then the rest; newest registration first within each.
- Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/LymphomaNot yet recruitingNCT07774377Phase 3
- Golidocitinib and Chidamide for Cutaneous T-Cell LymphomaRecruitingNCT07754890Phase 1/2
- The Efficacy of CAPCT in Patients With PTCLNot yet recruitingNCT07746245Phase 2
- Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic SyndromesNot yet recruitingNCT07616336Phase 2
- Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingNCT07601607Phase 1/2
- Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic CholangiocarcinomaRecruitingNCT07570849Phase 2
- Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After RadiotherapyRecruitingNCT07545967Phase 1
- Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine CarcinomaRecruitingNCT07518602Phase 2
- Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid LeukaemiaRecruitingNCT07514936Phase 3
- Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic LeukemiaRecruitingNCT07512700Phase 2
- Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete RemissionRecruitingNCT07507318Phase 2
- Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCLNot yet recruitingNCT07493330Phase 1/2
- Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLRecruitingNCT07493148Phase 2
- Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPRecruitingNCT07493109Phase 3
- Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCLNot yet recruitingNCT07415980Phase 1/2
- A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) ExpressionRecruitingNCT07412262Phase 2
- CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLRecruitingNCT07397832Phase 2
- Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.Not yet recruitingNCT07320963Phase 1/2
- Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AMLRecruitingNCT07304232Phase 2
- Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsRecruitingNCT07159620Phase 2
- Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaNot yet recruitingNCT07139353Phase 1/2
- Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT07093710Phase 1/2
- Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.Not yet recruitingNCT07081607Phase 2
- A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal CancerRecruitingNCT06979908Phase 2
- QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic CancerRecruitingNCT06951997Phase 2
- Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell PhenotypeRecruitingNCT06947967Phase 3
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML PatientsRecruitingNCT06928376Phase 2
- Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular SubtypesRecruitingNCT06891157Phase 2
- Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell LymphomaNot yet recruitingNCT06757387Phase 1/2
- A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal CancerNot yet recruitingNCT06745193Phase 2
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingNCT06739395Phase 2
- Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal CancerRecruitingNCT06685276Phase 2
- Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCLRecruitingNCT06570447Phase 2
- Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically RemovedNot yet recruitingNCT06547476Phase 2
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLNot yet recruitingNCT06516978Phase 2
- A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer PatientsRecruitingNCT06497985Phase 3
- Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AMLRecruitingNCT06451861Phase 2
- Linperlisib Combined With Chidamide in Patients With PTCLRecruitingNCT06421948Phase 1/2
- Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT06386302Not applicable
- A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALLRecruitingNCT06220487Phase 2
- A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver MetastasesNot yet recruitingNCT06218888Phase 2
- Tucidinostat Plus Apatinib for Advanced OsteosarcomaNot yet recruitingNCT06125171Phase 2
- A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma PatientsNot yet recruitingNCT06087419Phase 1/2
- Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06084819Phase 2
- A Study of Chidamide With AZA in MRD Positive AML After TransplantRecruitingNCT06066905Not applicable
- Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast CancerRecruitingNCT05983107Phase 2
- Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)RecruitingNCT05976997Phase 2
- Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell LymphomaRecruitingNCT05958719Phase 2
- A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line ChemotherapyRecruitingNCT05890287Not applicable
- Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic LeukemiaRecruitingNCT05881265Phase 2
- Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)RecruitingNCT05833724Phase 2
- Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL PatientsRecruitingNCT05823701Phase 2
- Chidamide Prevents Recurrence of High-risk AML After Allo-HSCTRecruitingNCT05682755Phase 1/2
- AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFHEnrolling by invitationNCT05678933Phase 3
- Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast CancerRecruitingNCT05633914Phase 2
- Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell PhenotypeRecruitingNCT05572983Phase 2
- Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic LeukemiaRecruitingNCT05566054Phase 2
- A Umbrella Study in R/R PTCL Guided by Molecular SubtypesRecruitingNCT05559008Phase 1/2
- ChiCGB vs BEAM in High-risk or R/R LymphomasRecruitingNCT05466318Phase 3
- Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With PalbociclibRecruitingNCT05464173Phase 1/2
- Chidamide Bridging for CAR-T TherapyRecruitingNCT05370547Phase 1/2
- Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
- Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood.RecruitingNCT05338541Phase 1
- Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid TumorsRecruitingNCT05320640Phase 1/2
- Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia RelapseRecruitingNCT05270200Phase 1/2
- An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast CancerRecruitingNCT05186545Phase 2
- Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric CancerRecruitingNCT05163483Phase 2
- Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCLRecruitingNCT04994210Phase 2
- The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.RecruitingNCT04514081Phase 2
- Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen ReceptorRecruitingNCT04337606Phase 1/2
- Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT04329130Phase 2
- Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin LymphomaRecruitingNCT04233294Phase 2
- Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCLNot yet recruitingNCT04052659Phase 2
- A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung CancerTerminatedNCT05141357Phase 2Results posted
- Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)CompletedNCT02955589Phase 2Results posted
- Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)CompletedNCT02953652Phase 2Results posted
- A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).Active, not recruitingNCT06550336Phase 2
- Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell LymphomaActive, not recruitingNCT06492629Phase 2
- Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT06068621Phase 2
- Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell LymphomasCompletedNCT05991973Phase 2
- Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) PatientsStatus unknownNCT05951855Phase 2
- Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)TerminatedNCT05770882Phase 1/2
- Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.Status unknownNCT05749575Phase 2
- Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast CancerStatus unknownNCT05747313Phase 1/2
- Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb StudyCompletedNCT05586841Phase 1
- A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLCCompletedNCT05519865Phase 2
- A Multicenter Randomized Open-label Study of Chidamide Plus HD-DEX Versus HD-DEX in ITPStatus unknownNCT05411874Phase 2
- Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.Status unknownNCT05411380Phase 2
- Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BCStatus unknownNCT05400993Phase 2
- Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical TrialStatus unknownNCT05390476Phase 2
- Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor FailureTerminatedNCT05335473Phase 1/2
- Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid LeukemiaStatus unknownNCT05330364Phase 2
- Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)TerminatedNCT05281276Phase 1
- Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 InhibitorsStatus unknownNCT05191914Phase 4
- Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell LymphomaStatus unknownNCT05179213Phase 2
- Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHDStatus unknownNCT05140616Phase 1/2
- Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine NeoplasmStatus unknownNCT05113355Phase 2
- Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast CancerStatus unknownNCT05085626Phase 2
- PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell LymphomaTerminatedNCT05083208Phase 1
- Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine CarcinomaStatus unknownNCT05076786Phase 2